Other agents that are under investigation in glioblastoma effecting this pathway are PI3K inhibitors (e.g., buparlisib, GDC-0084), dual PI3K/mTOR inhibitors (e.g., dactolisib) or mTOR inhibitors (e.g., AZD8055) [51,52]. This evidence concerns the gene MTOR and glioblastoma.